Roche Ramps Up Sales Force For U.S. Launch Of HPV Test
This article was originally published in The Gray Sheet
Executive SummaryRoche has been hiring additional sales reps and training its existing sales force in preparation for the U.S. launch of its cobas HPV test to identify women at high risk of developing cervical cancer.
You may also be interested in...
The Microbiology Devices Panel provided unanimous support Roche’s submission to upgrade labeling for it cobas HPV test as a first-line, primary screen for cervical cancer.
Japanese authority approves St. Jude’s MRI-safe pacemaker and Edwards’ Sapien XT, the first transcatheter aortic valve approved in that country. More new products.
Lab diagnostic products will actually account for a larger portion of Hologic’s business post-acquisition than the firm’s core mammography, ultrasound and magnetic resonance imaging offerings.